Revive Biotechnology
Revive Biotech: Innovating nanotech solutions for ocular health, focusing on retinal artery occlusion.
Founded
2018Revive Biotech: Innovating nanotech solutions for ocular health, focusing on retinal artery occlusion.
Revive Biotechnology was founded with the mission to address the significant unmet need of blinding retinal diseases caused by tissue hypoxia. The company focuses on developing innovative nanotechnology solutions to improve oxygen delivery to hypoxic tissues, specifically targeting conditions like central retinal artery occlusion and other ocular ischemic diseases. Their core product involves nano-carriers designed for the immediate and targeted delivery of oxygen, aiming to enhance visual outcomes and improve the quality of life for affected patients.
Notable affiliated individuals include leading experts in ophthalmology and nanotechnology, who contribute to the company's cutting-edge research and development. Revive Biotechnology has garnered attention from prominent investors in the biotech sector, supporting its mission to revolutionize ocular health. Key achievements include significant advancements in their nano-carrier technology and successful preclinical trials, positioning the company as a promising innovator in the field of ophthalmology. The overall impact of Revive Biotechnology lies in its potential to transform treatment paradigms for retinal diseases, offering hope to millions of patients worldwide.
Companies similar to Revive Biotechnology include Aurion Biotech, Regennova, ReviveMed and EyeCyte.
Revive Biotechnology was founded in 2018.
Revive Biotechnology's headquarters is located in Champaign, IL, US.
Revive Biotechnology's most recent funding round was for $256k (USD) in November 2020.
As of Nov 24, 2020, Revive Biotechnology has raised a total of $256k (USD).
Revive Biotechnology has 2 employees as of Feb 4, 2024.
ReviveMed
